Technology / Science
A Future Standard of Care
Technology
Contact Lens Drug
Delivery Platform
We have proprietary printing technology and ink that allows for the sustained, continuous release of ophthalmic drugs via contact lenses and it is called the MediPrint™ process.
Our unique process results in a novel way to for treat various eye diseases and conditions with a non-invasive, cost-effective treatment.
We have an extensive global patent portfolio, comprising intellectual property around the world and covering glaucoma, dry eye, myopia, etc.
MediPrint™ lenses are the
convenient, efficient and comfortable way to deliver
ocular medications to the eye non-invasively.
Eye Care
Patients
• No daily drops
• Continuous therapy
Eye Care
Payers
• Cost neutrality
• More satisfied members and providers
Eye Care
Professionals
• Higher patient satisfaction
• Greater income potential
Technology
Current Treatments’ Shortcomings
While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they are plagued by only around a 50% compliance rate, by low bioavailability and by side effects.
This leads millions to continue to suffer, including from disease progression, and even thousands to experience preventable blindness.
There are vast unmet needs for better non-invasive and cost-effective treatment options in numerous multi-billion dollar markets.
Technology
Proprietary MediPrint™ Process
Unique contact lens drug delivery platform for effectively treating ocular diseases.
Unique Process
Our unique process results in a novel way to treat various eye diseases and conditions with a non-invasive, cost-effective treatment.
Drug Delivery
Drug delivery via contact lenses may have many benefits, including improved bioavailability, better patient compliance and reduced side effects.
Manufacturing
The innovative MediPrint™ solution also mitigates regulatory risks, works seamlessly with existing high speed manufacturing processes and offers eye care professionals new treatment choices.
The value-added benefits may make these a first line choice for treatments